Today

Agents

Chat

Arena

Discover

More

App

Chemours Q2 Adjusted EPS USD 0.42 Vs. IBES Estimate USD 0.42 - CC News | Rallies

Chemours Q2 Adjusted EPS USD 0.42 Vs. IBES Estimate USD 0.42

CC•2026-08-04

Chemours reports Q2 adjusted results versus estimates

Aug. 4 (Reuters) - Chemours Q2 adjusted net income was USD 64 million versus the IBES estimate of USD 60.7 million.

Q2 adjusted EBITDA was USD 247 million versus the IBES estimate of USD 238.1 million
Q2 sales were USD 1,600 million versus the IBES estimate of USD 1,654 million

Related News

General Dynamics EVP Marguerite Amy Gilliland sells USD 16.49 million in common shares

GD•2026-08-04

Rigel Pharmaceuticals posts corporate deck highlighting VEPPANU in-license and commercial launch plan

RIGL•2026-08-04

Sight Sciences wins FDA 510(k) clearance for OMNI Ultra glaucoma system

SGHT

•

2026-08-04

VeriSign EVP, General Counsel and Secretary Thomas C. Indelicarto sells 500 shares for $146,100

VRSN•2026-08-04

Mattel reiterates annual forecasts, misses quarterly profit estimate on higher costs

MAT•2026-08-04